

Drug Utilization Review Board
(DUR Board)
Meeting – August 12, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. July 8, 2009 DUR Minutes – Vote
 - B. July 9, 2009 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for April 2009
 - B. Retrospective Drug Utilization Review Response for March 2009
 - C. Medication Coverage Activity Audit for July 2009
 - D. Help Desk Activity Audit for July 2009
 - E. Medication Therapy Management Services Activity Audit for FY 2009

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

- 5. Action Item – Vote to Prior Authorize Gelnique™ and Update Bladder Control Product Based Prior Authorization Category – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 6. Action Item – Vote to Apply Quantity Restrictions to Hydrocodone Products – See Appendix D.**
 - A. COP Recommendations
 - B. SoonerCare Program Operations and Benefits Update – OHCA Staff
 - C. SoonerCare Quality Assurance / Quality Improvement Update – OHCA Staff

Items to be presented by Dr. Keast, Dr. Chonlahan, Dr. Muchmore, Chairman

7. **60 Day Notice to Prior Authorize Otic Anti-Infective Products – See Appendix E.**
 - A. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Patel, Dr. Muchmore, Chairman

8. **60 Day Notice to Prior Authorize Fibromyalgia Products – See Appendix F.**
 - A. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Nesser, Dr. Muchmore, Chairman

9. **SoonerCare Program Overview**

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix G.**

11. **Future Business**
 - A. Synagis Annual Review
 - B. Anxiolytic Criteria Review
 - C. New Product Reviews
 - D. Annual Reviews

12. **Adjournment**